Active substances: Hydroxyzine
+ free Atarax pill.
No use, distribution or reproduction is other articles in PMC.
Two open-label trials by Raby and Coomaraswamy 72 and Haney et al. Two of these studies, Heinzerling et al. Only the Urschel III et al. More recently, several pharmacotherapies have been explored through many clinical trials with some mixed results 82, 83.
However, no pharmacologic treatment has emerged as clearly efficacious 84. Mason et al. All subjects received weekly individual counseling as well 85.
Discussion There is growing evidence that GBP is effective in the treatment of various psychiatric and substance use disorders. However, GBP is currently approved for use only as an anticonvulsant and analgesic.
In support of this, we carried out a systematic review of existing studies on the efficacy of GBP for the treatment of psychiatric disorders and comorbidities 86. These studies were then classified based on the disorder being investigated and analyzed to extract the study findings.
Overall, most of the studies, such as Pande et al. While a small number of studies such as Anton et al.
These studies reported some beneficial evidence in support of GBP's use in psychiatric disorders. Based on our review of the published literature and existing data, GBP appears to be effective in the treatment of various anxiety disorders of mild to moderate severity.
Anxiety disorders such as generalized anxiety disorder, social phobia, and a fear of public speaking have been studies in patients with good clinical response to GBP 10, 12 — 14, 87.
Also, GBP has been found effective in particular settings such as reduction of perioperative anxiety 7, 11, 15, 16. The anxiolytic of GBP is established in both human and animal models studies 88.